The verdict
Our read at a glance.
Whether PYY3-36's appetite-reducing biology translates into meaningful, tolerable weight loss as a treatment, on its own or in combinations.
- The signal
- Human studies show PYY3-36 reduces food intake and appetite, but as a standalone agent its weight effects have been modest and often limited by nausea. It is mainly pursued in combinations and as a target for longer-acting analogs. It is not approved.
- The unknown
- Whether PYY-based approaches can produce meaningful weight loss with acceptable tolerability, especially as analogs or in combination with GLP-1.
- Our read
- A real appetite hormone with modest standalone results, not a finished weight-loss drug. PYY3-36 clearly reduces appetite, but nausea and limited solo effect mean its promise is mostly as an analog or a GLP-1 combination partner, all still investigational.
The mechanism
How it works.
PYY3-36 is the active fragment of peptide YY, a hormone released by cells in the lower gut after a meal. It travels to the brainstem and hypothalamus and activates the Y2 receptor, which dampens the appetite-stimulating signals that drive hunger, so people eat less at the next meal. That short-term reduction in food intake is well documented in human infusion studies, but as a standalone injection its weight effect has been small and is capped by nausea.
Safety & regulatory boundary
The consequential part.
PYY3-36 is not an approved drug. Its main dose-limiting effect in studies has been nausea, and its standalone weight effect is modest. Research-labeled or compounded PYY is not an approved product, and its appetite biology does not establish a proven weight-loss treatment. It is investigational and not for use outside research.
What's next
What we're watching.
Longer-acting PYY analogs, combination trials with GLP-1, and tolerability data.
Context
Why this is discussed.
PYY3-36 is a natural appetite-reducing gut hormone, which makes it a long-standing target for obesity drugs and a frequent partner for GLP-1 in combination research.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2024-01-24
ClinicalTrials.gov · RECRUITING · 2024-02-13
ClinicalTrials.gov · NA · COMPLETED · 2024-03-25
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2024-09-23
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-04
ClinicalTrials.gov · NA · RECRUITING · 2025-05-23
ClinicalTrials.gov · NA · COMPLETED · 2025-04-01
ClinicalTrials.gov · PHASE4 · COMPLETED · 2022-06-01
Indexed literature (PubMed)12
Hong SH et al. · Curr Opin Endocrinol Diabetes Obes · 2024
Sumithran P et al. · N Engl J Med · 2011
Valassi E et al. · Nutr Metab Cardiovasc Dis · 2008
Chandarana K et al. · Curr Opin Endocrinol Diabetes Obes · 2008
Chaudhri OB et al. · Int J Obes (Lond) · 2008
Akhlaghi M · Crit Rev Food Sci Nutr · 2024
Steinert RE et al. · Physiol Rev · 2017
Lafferty RA et al. · Peptides · 2018
le Roux CW et al. · Proc Nutr Soc · 2005
Chen W et al. · Bioorg Chem · 2023
Karra E et al. · J Physiol · 2009
Olsen J et al. · Peptides · 2016
Keep reading